![]() Mmol of potassium (Ellenhorn and Barceloux, 1988). MEq of potassium per day and 40 to 100 mEq or more perĭay for the treatment of potassium depletion.ģ.0 g of potassium chloride contain approximately 40 Prevention of hypokalaemia the usual dose is 20 to 30 In case of potassium deficiency, the dose should beĪdjusted to the needs of the patient. It is also used in the treatment ofĬumulative digitalis poisoning. When thiazide diuretics or corticosteroids are used inĬase of excessive vomiting or diarrhoea, or diets poor USES 4.1 Indications Prevention and treatment of potassium deficiency, e.g. 3.4.2 Shelf-life of the locally available formulation Solid phase in airtight container - five years. Melting point 773☌ 3.3.2 Properties of the locally available formulationģ.4 Other characteristics 3.4.1 Shelf-life of the substance ![]() Or colourless crystals, with saline taste, Or crystalline powder or white granular powder Normal state at room temperature: white crystals MW: 74.55 (K 52,4%, Cl 47,6%) 3.3 Physical properties 3.3.1 Properties of the substance A large number of salts exist of which potassiumĬhloride is one. PHYSICO-CHEMICAL PROPERTIES 3.1 Origin of the substance Potassium is a natural element which is never found free in These regimes shift potassium into cells they do Infusion of sodium bicarbonate, glucose plus insulin, orĭialysis. Reduce the plasma concentration of potassium by 2.4 First aid measures and management principles Basic life support measures are essential in severely poisonedĮstablish IV-line, obtain blood sample for electrolytes, BUN,Ĭontinuous ECG monitoring should be started Ĭardiac dysrhythmias should be controlled with an appropriateĮmesis or gastric lavage should be performed as soon asĬonsult the treatment protocol on the management of The presence of hyperkalaemia and electrocardiographicĬhanges. Patient: vomiting, diarrhoea, muscular cramps, hypotension 2.3 Diagnosis The diagnosis is based on the clinical presentation of the 2.2 Summary of clinical effects Vomiting, diarrhoea, listlessness, muscular cramps, Inflammation may develop from intravenous or subcutaneousĪdministration. Gastrointestinal ulceration may be caused by enteric-Ĭoated potassium chloride tablets. SUMMARY 2.1 Main risks and target organs Cardiac and related effects are the most important risks of Proten Robin San-Bolagen Sandoz-Wander ScheringĬorp/Essex Sheuli Sopar Sterop Upsher-Smith 2. Liorens Mead-Johnson Nordmark Panray Petersen Pfizer Myers CA Roy Ciba Ciba-Geigy Collett-Marwell Columbiaĭrug Ferrosan Fleming Gama-Geve Giulini Hässle ICN Leo (USA) 1.6 Manufacturers, Importers Abbott Adria Astra Baxter Beecham Benzo Borlex Bristol. Klorfen, Klorvess 10% Liquid, Klotrix, K-lyte/Cl, Pan-Kloride, Kaochlor, Kaochlor S-F, Kaon-Cl, Kato, Kay Ciel, Klor, Klor. Kaleorid, Kalilente, Kalipor, Kalitabs, Kalium-Duretter ![]() Kaleorid, Kalilente, Kalium duretter, Kali Retard (Norway) Kalinor, Kalcium-Duriles, Rekawan (Germany) Kaochlor, Kay Ciel, K-lyte/C1, K-10 Solution, Roychlor Potavescent Rekawan Repone K Slow-K Span-KĬhlorvescent, K-San, Kay Ciel, Span-K (Australia)Ĭhloropotassuril, Kalium Durettes, Steropotassium, Ultra-K. Tab Lento-Kalium Leo K Micro K Nu-K Peter-Kal PfiKlor Potassium chloride Kaleorid Kalitabs Kalium-Duriles Kaon-Ĭl Kaskay Kayback Kay-Cll-L K-Contin Klor-Con K-Norm K. NAME 1.1 Substance Potassium chloride 1.2 Group Electrolytes/agents 1.3 Synonyms Chlorure de potassium Cloreto de potassio Cloruro de potasio Kalii chloridum Kalium chloratum Potassi chloridum Sylvine 1.4 Identification numbers 1.4.1 CAS numberġ.5 Brand names, Trade names Camcopot Chloropotassuril Chlorvescent ClK Diffu-K Enseal AUTHOR(S), REVIEWER(S), DATE(S) (INCLUDING UPDATES), COMPLETE ADDRESS(ES)ġ. ![]() TOXICOLOGICAL ANALYSES AND BIOMEDICAL INVESTIGATIONSĨ.1.2 Storage of laboratory samples and specimensĨ.1.3 Transport of laboratory samples and specimensĨ.2 Toxicological Analyses and Their InterpretationĨ.2.1 Tests on toxic ingredient(s) of materialĨ.2.1.2 Advanced Qualitative Confirmation Test(s)Ĩ.2.2.2 Advanced Qualitative Confirmation Test(s)Ĩ.2.3 Interpretation of toxicological analysesĨ.3 Biomedical investigations and their interpretationĨ.3.4 Interpretation of biomedical investigationsĨ.4 Other biomedical (diagnostic) investigations and their interpretationĨ.5 Overall Interpretation of all toxicological analyses and toxicological investigationsĩ.4 Systematic description of clinical effectsĩ.4.9 Eye, ear, nose, throat: local effectsĩ.4.12.2 Fluid and electrolyte disturbancesġ0.3 Life supportive procedures and symptomatic/specific treatmentġ4. NAMEĢ.4 First aid measures and management principlesģ.3.2 Properties of the locally available formulationģ.4.2 Shelf-life of the locally available formulationģ.4.5 Specific properties and compositionĦ.3 Biological half-life by route of exposureĨ. Potassium chloride (PIM 430) Potassium chloride 1.
0 Comments
Leave a Reply. |